FDA's oncology head Rick Pazdur defends the accelerated approval pathway, claiming it is 'under attack'
The FDA is sounding the alarm over its accelerated approval pathway as backlash continues over the recent nod in favor of Biogen’s Alzheimer’s drug Aduhelm, and an ODAC meeting on six such approvals that could potentially be pulled from the market — two of which already have.
“Do you think accelerated approval is under attack? I do,” Rick Pazdur, head of FDA’s Oncology Center of Excellence, said at a Friends of Cancer Research webinar on Thursday.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.